A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy

Trial Profile

A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Venetoclax (Primary) ; Azacitidine; Decitabine; Posaconazole
  • Indications Acute myeloid leukaemia
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 03 Apr 2018 The primary endpoint has been changed from Adverse Event to Overall Survival.
    • 12 Jan 2018 Safety and preliminary results (n=45 in main study and 12 in substudy; as of 15 Jun 2016) published in the Lancet Oncology.
    • 12 Dec 2017 Results (n=145; Data cut-off: February 17, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top